Home LiteratureArticle Details
PMID: 2154620 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.

Journal of virology ·Vol. 64 ·No. 3 ·1990-03-00 ·Pages 1398-401

Bejarano MT, Masucci MG, Morgan A, Morein B, Klein G, Klein E

Abstract

The ability of B cells, B blasts, and macrophages to present Epstein-Barr virion antigens to autologous T cells and trigger their capacity to inhibit Epstein-Barr virus-induced B-cell transformation was tested. Macrophages were as efficient as B cells and B blasts in presenting the virus to T lymphocytes. This function required antigen processing, because it was inhibited by chloroquine treatment and by fixation of the antigen-presenting cells immediately after viral exposure but not 18 h later. T cells exposed to the purified Epstein-Barr virus envelope antigen gp350 coupled to immunostimulating complexes also showed inhibitory function. These results suggest that recognition of processed virion antigens elicits the generation of T-cell-mediated inhibition of Epstein-Barr virus-induced B-cell transformation.

MeSH Terms
Antigens, Viral/immunology B-Lymphocytes/immunology Cells, Cultured Herpesvirus 4, Human/immunology Humans Lymphocyte Activation Macrophages/immunology T-Lymphocytes/immunology Virion/genetics
Chemicals
Antigens, Viral
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Bejarano M T
Department of Tumor Biology, Karolinska Institutet, Stockholm, Sweden.
Masucci M G
Morgan A
Morein B
Klein G
Klein E
References (38)
38 references, click to expand
  1. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
    Proc Natl Acad Sci U S A. 1980 May;77(5):2979-83 PMID: 6248876
  2. Specificity and function of T cells bearing gamma delta receptors.
    Immunol Today. 1988 Mar;9(3):73-6 PMID: 2978457
  3. Stages of B cell differentiation in human lymphoid tissue.
    J Exp Med. 1981 Sep 1;154(3):737-49 PMID: 7024458
  4. Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line.
    Int J Cancer. 1981 May 15;27(5):593-601 PMID: 6169663
  5. Long-term T-cell-mediated immunity to Epstein-Barr virus.
    Cancer Res. 1981 Nov;41(11 Pt 1):4216-21 PMID: 6272965
  6. Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein.
    J Immunol. 1982 Aug;129(2):814-8 PMID: 7086144
  7. Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells.
    J Virol. 1982 Jan;41(1):286-97 PMID: 6283120
  8. Expression of target antigen for Epstein-Barr virus-specific cytotoxic T cells on BJAB cells freshly infected with EBV.
    Microbiol Immunol. 1982;26(7):575-83 PMID: 6290853
  9. C3d receptors are expressed on human monocytes after in vitro cultivation.
    Proc Natl Acad Sci U S A. 1983 Apr;80(8):2351-5 PMID: 6601277
  10. Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells.
    Cell Immunol. 1983 Mar;76(2):311-21 PMID: 6301696
  11. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing.
    J Exp Med. 1983 Aug 1;158(2):303-16 PMID: 6193218
  12. Replication of Epstein-Barr virus in human epithelial cells infected in vitro.
    Nature. 1983 Dec 1-7;306(5942):480-3 PMID: 6316160
  13. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.
    Nature. 1984 Mar 29-Apr 4;308(5958):457-60 PMID: 6709052
  14. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.
    Int J Cancer. 1985 Jan 15;35(1):35-42 PMID: 2981780
  15. In vitro analysis of the Epstein-Barr virus: host balance in long-term renal allograft recipients.
    Int J Cancer. 1985 Jan 15;35(1):43-9 PMID: 2981781
  16. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
    J Immunol. 1985 Apr;134(4):2571-9 PMID: 3156185
  17. Cytotoxic T cells recognize fragments of the influenza nucleoprotein.
    Cell. 1985 Sep;42(2):457-67 PMID: 2411422
  18. Role of T cell subpopulations in the control of the proliferative potential of EBV transformed B cells.
    Behring Inst Mitt. 1983 May;(72):163-8 PMID: 6152688
  19. Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones.
    J Exp Med. 1986 Apr 1;163(4):903-21 PMID: 3485173
  20. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.
    Science. 1986 Dec 19;234(4783):1563-6 PMID: 2431484
  21. Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth.
    Int J Cancer. 1987 Apr 15;39(4):472-6 PMID: 3030940
  22. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
    J Virol. 1987 May;61(5):1416-20 PMID: 3033269
  23. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein.
    Proc Natl Acad Sci U S A. 1987 Aug;84(15):5384-8 PMID: 3037547
  24. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.
    Nature. 1988 Feb 25;331(6158):719-21 PMID: 2830541
  25. Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography.
    J Immunol Methods. 1988 Apr 6;108(1-2):231-6 PMID: 2832478
  26. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    J Immunol. 1988 Jun 1;140(11):3867-74 PMID: 2836501
  27. The requirement of lipids for the formation of immunostimulating complexes (iscoms).
    Biotechnol Appl Biochem. 1988 Apr;10(2):161-72 PMID: 2838046
  28. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.
    J Virol. 1988 Aug;62(8):2614-21 PMID: 2839689
  29. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.
    J Gen Virol. 1988 Aug;69 ( Pt 8):2093-6 PMID: 2841417
  30. T-cell-mediated inhibition of EBV-induced B-cell transformation: recognition of virus particles.
    Int J Cancer. 1988 Sep 15;42(3):359-64 PMID: 2843474
  31. Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells.
    Cell. 1988 Dec 2;55(5):837-47 PMID: 2847872
  32. Intestinal intraepithelial lymphocytes are a distinct set of gamma delta T cells.
    Nature. 1988 Dec 1;336(6198):479-81 PMID: 2461518
  33. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
    Eur J Immunol. 1988 Nov;18(11):1689-97 PMID: 2904885
  34. Polyomavirus DNA is damaged in target cells during cytotoxic T-lymphocyte-mediated killing.
    J Virol. 1989 Feb;63(2):572-8 PMID: 2536092
  35. Two related Epstein-Barr virus membrane proteins are encoded by separate genes.
    J Virol. 1989 Feb;63(2):933-7 PMID: 2536113
  36. Class I-restricted presentation occurs without internalization or processing of exogenous antigenic peptides.
    J Immunol. 1989 Feb 15;142(4):1079-83 PMID: 2492575
  37. Viral latency and transformation: the strategy of Epstein-Barr virus.
    Cell. 1989 Jul 14;58(1):5-8 PMID: 2546674
  38. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
    Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307-11 PMID: 6254073
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.64.3.1398-1401.1990
Published
1990-03-00
Pages
1398-401
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC249265
Subset
IM
Grants
NCI NIH HHS · 5ROI CA 30264 · United States
External Links
PubMed source DOI: 10.1128/JVI.64.3.1398-1401.1990 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2